ESMO Media Releases

Guidelines reflect personalised treatment approach

AIOM adopts ESMO Open as its scientific journal

Phase III trial finds excellent safety and tolerability

Phase III trial confirms efficacy and safety of new second-line agent

Phase III trial finds no significant difference in overall survival

Phase I trial achieves partial responses and is well tolerated

The European Medicines Agency (EMA) and the European Society for Medical Oncology (ESMO) will host a workshop on single-arm trials (SATs) at the EMA headquarters in London, UK, on June 30th 2016.

A total of 15 oncologists from 12 European countries* have been chosen to participate in the first ESMO Leaders Generation Programme designed to develop the careers of oncology’s future leaders.

Nearly 2,900 abstracts were submitted for inclusion within the ESMO 2016 Congress, marking a 70% increase over the past six years and confirming the ESMO Congress as the leading oncology event in Europe...

The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland

Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland

Press Statement: ESMO Welcomes Final Version of European Data Protection Regulation